#United States #Detroit #Karmanos Cancer Institute #Hemophilia B #Hemegenix

Pioneering Gene Therapy for Hemophilia B at Karmanos Cancer Institute

The Barbara Ann Karmanos Cancer Institute has made history by becoming the first and only independent cancer center in the United States to offer a groundbreaking gene therapy for patients suffering from Hemophilia B. This innovative treatment, known as Etranacogene dezaparvovec-drlb (marketed as Hemegenix®), has recently received FDA approval, providing adult patients an unprecedented opportunity for improvement in their quality of life.

A New Hope for Hemophilia B Patients

Hemophilia B is a genetic disorder that affects blood clotting due to a deficiency of factor IX, leading to excessive bleeding after injuries or surgery. Those diagnosed with this rare condition often rely on consistent medical care, traditionally involving regular infusions of factor IX replacement therapy to minimize bleeding risks. However, the approval of Hemegenix signifies a revolutionary shift.

Steve W., a resident of Clinton Township, was the first patient to receive this gene therapy at Karmanos Cancer Center on October 28, 2025. Reflecting on his treatment, Steve expressed his gratitude, noting, "I'm just very blessed to be in the right spot at the right time with the right people. And it's working. I didn't have any problems the first few days… I did have some days where I was just tired, but about a week after the infusion, I was good."

How Gene Therapy Works

The gene therapy process involves inserting a gene that codes for factor IX into a vector with an inactive viral capsid, which is then infused into the patient. This vector targets the liver, enabling it to produce the missing factor IX protein. Following the infusion, patients are monitored closely (for at least three hours) to ensure their safety and to observe any potential infusion-related reactions.

Dr. Indryas Woldie, a specialist in hematological diseases and head of Karmanos’ Hemophilia and Other Bleeding Disorders Clinic, explains that patients can start producing their own factor IX as early as a few weeks post-infusion, with long-term efficacy showing promising results. In fact, during international clinical trials, an impressive 94% of patients discontinued their routine factor IX prophylaxis after receiving the treatment.

The Journey to Treatment

Before becoming a treatment center for this revolutionary gene therapy, Karmanos underwent rigorous preparations that included comprehensive training for its healthcare teams—physicians, pharmacists, and nurses alike. This meticulous learning process was critical to guarantee the safe administration of infusions and appropriate post-treatment care.

Surender Kanaparthi, the Chief Pharmacy Officer at Karmanos, stated, "Our mission has always been to expand access to the most advanced treatments available, and gene therapy is the future of hematology and oncology care." The hope is that this innovative therapy will lead to a significant change in the standard care of Hemophilia B patients.

Eligibility Criteria

To qualify for this gene therapy, patients must currently be undergoing factor IX prophylaxis treatment, have experienced life-threatening bleeding episodes, or suffer from repeated severe spontaneous bleeding. Interested individuals can learn more about the eligibility criteria by visiting the Karmanos website.

Transforming Lives

As a part of McLaren Health Care, the Karmanos Cancer Institute holds a reputation as a leader in cancer care and research. The comprehensive care framework, along with academic partnerships for research and education, positions Karmanos at the forefront of innovative treatments like Hemegenix.

Steve’s story exemplifies the transformative potential of this therapy, highlighting the hope offered to many who endure this debilitating disorder. With ongoing advancements in treatments, we are moving towards a future where patients with Hemophilia B can lead fuller, more active lives. For more information on this revolutionary treatment and to assess eligibility, individuals may call 1-800-KARMANOS or visit karmanos.org/hemgenix.

Karmanos Cancer Institute continues to embody a commitment to battling cancer and enhancing patient outcomes with compassion, courage, and state-of-the-art medical care.